Literature DB >> 23891794

Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson's disease.

Amélie C Lanoue1, Gene J Blatt, Jean-Jacques Soghomonian.   

Abstract

It has recently been shown that expression of the rate-limiting GABA-synthesizing enzyme glutamic acid decarboxylase (GAD) is decreased in Brodmann area 9 (BA9) of the dorsolateral prefrontal cortex (DLPFC) in Parkinson's disease (PD) compared to control brains (Lanoue, A.C., Dumitriu, A., Myers, R.H., Soghomonian, JJ., 2010. Exp. Neurol. 206 (1), 207-217). A subpopulation of cortical GABAergic interneurons expresses the calcium-binding protein parvalbumin and plays a critical role in the control of pyramidal neuron excitability and the generation of cortical gamma frequency oscillations. In view of its key role in the physiology of the cerebral cortex, we sought to determine whether the expression of parvalbumin and the number of parvalbumin-expressing neurons are altered in BA9 of PD brains. First, isotopic in situ hybridization histochemistry was used to examine mRNA expression of parvalbumin on post-mortem brain sections. Second, immunohistochemistry and design-based stereology were used to determine the density of parvalbumin-positive interneurons in BA9. Quantification of mRNA labeling at the single cell level showed a significant decrease in parvalbumin expression in PD cases. In contrast, neuronal density of parvalbumin-positive neurons was not significantly different between PD and controls. Results confirm that the GABAergic system is altered in the DLPFC in PD and identify the contribution of parvalbumin-expressing neurons in these alterations. We speculate that these effects could contribute to altered cortical excitability and oscillatory activity previously documented in PD.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GABA; Gene expression; Parkinson′s disease; Parvalbumin; Prefrontal cortex; mRNA

Mesh:

Substances:

Year:  2013        PMID: 23891794      PMCID: PMC3816277          DOI: 10.1016/j.brainres.2013.07.025

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  65 in total

1.  Intracortical inhibition of the motor cortex in movement disorders.

Authors:  R Hanajima; Y Ugawa
Journal:  Brain Dev       Date:  2000-09       Impact factor: 1.961

2.  The efficiency of systematic sampling in stereology--reconsidered.

Authors:  H J Gundersen; E B Jensen; K Kiêu
Journal:  J Microsc       Date:  1999-03       Impact factor: 1.758

Review 3.  Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks.

Authors:  Marlene Bartos; Imre Vida; Peter Jonas
Journal:  Nat Rev Neurosci       Date:  2007-01       Impact factor: 34.870

4.  Tyrosine hydroxylase-immunoreactive neurons are decreased in number in the cerebral cortex of Parkinson's disease.

Authors:  T Fukuda; J Takahashi; J Tanaka
Journal:  Neuropathology       Date:  1999-01       Impact factor: 1.906

5.  GABAergic neuronal subtypes in the human frontal cortex--development and deficits in schizophrenia.

Authors:  G P Reynolds; C L Beasley
Journal:  J Chem Neuroanat       Date:  2001-07       Impact factor: 3.052

6.  Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus.

Authors:  Martin Vreugdenhil; John G R Jefferys; Marco R Celio; Beat Schwaller
Journal:  J Neurophysiol       Date:  2003-03       Impact factor: 2.714

7.  Shortened silent period produced by magnetic cortical stimulation in patients with Parkinson's disease.

Authors:  K Nakashima; Y Wang; M Shimoda; K Sakuma; K Takahashi
Journal:  J Neurol Sci       Date:  1995-06       Impact factor: 3.181

8.  Grey matter atrophy in cognitively impaired Parkinson's disease.

Authors:  Tracy R Melzer; Richard Watts; Michael R MacAskill; Toni L Pitcher; Leslie Livingston; Ross J Keenan; John C Dalrymple-Alford; Tim J Anderson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-09-02       Impact factor: 10.154

9.  Different distributions of GAD65 and GAD67 mRNAs suggest that the two glutamate decarboxylases play distinctive functional roles.

Authors:  S Feldblum; M G Erlander; A J Tobin
Journal:  J Neurosci Res       Date:  1993-04-15       Impact factor: 4.164

10.  Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia.

Authors:  Chul Hyoung Lyoo; Young Hoon Ryu; Myung Sik Lee
Journal:  Mov Disord       Date:  2010-03-15       Impact factor: 10.338

View more
  10 in total

1.  Predictive encoding of motor behavior in the supplementary motor area is disrupted in parkinsonism.

Authors:  Claudia M Hendrix; Brett A Campbell; Benjamin J Tittle; Luke A Johnson; Kenneth B Baker; Matthew D Johnson; Gregory F Molnar; Jerrold L Vitek
Journal:  J Neurophysiol       Date:  2018-06-06       Impact factor: 2.714

2.  Retinoic Acid Prevents the Neuronal Damage Through the Regulation of Parvalbumin in an Ischemic Stroke Model.

Authors:  Ju-Bin Kang; Dong-Ju Park; Phil-Ok Koh
Journal:  Neurochem Res       Date:  2022-10-16       Impact factor: 4.414

3.  Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks.

Authors:  Sabina Marciano; Tudor M Ionescu; Ran Sing Saw; Rachel Y Cheong; Deniz Kirik; Andreas Maurer; Bernd J Pichler; Kristina Herfert
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-26       Impact factor: 12.779

4.  Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  Lacey Pflibsen; Katherine A Stang; Michelle D Sconce; Vanessa B Wilson; Rebecca L Hood; Charles K Meshul; Suzanne H Mitchell
Journal:  J Neurosci Res       Date:  2015-08-31       Impact factor: 4.164

5.  Progression Rate Associated Peripheral Blood Biomarkers of Parkinson's Disease.

Authors:  Yanxia Fan; Shuping Xiao
Journal:  J Mol Neurosci       Date:  2018-06-23       Impact factor: 3.444

Review 6.  The role of Ca2+ signaling in Parkinson's disease.

Authors:  Sofia V Zaichick; Kaitlyn M McGrath; Gabriela Caraveo
Journal:  Dis Model Mech       Date:  2017-05-01       Impact factor: 5.758

Review 7.  Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson's Disease.

Authors:  Ane Murueta-Goyena; Ane Andikoetxea; Juan Carlos Gómez-Esteban; Iñigo Gabilondo
Journal:  Front Pharmacol       Date:  2019-10-30       Impact factor: 5.810

8.  Cerebellar GABA Levels and Cognitive Interference in Parkinson's disease and Healthy Comparators.

Authors:  Federica Piras; Daniela Vecchio; Francesca Assogna; Clelia Pellicano; Valentina Ciullo; Nerisa Banaj; Richard A E Edden; Francesco E Pontieri; Fabrizio Piras; Gianfranco Spalletta
Journal:  J Pers Med       Date:  2020-12-28

9.  Quercetin attenuates the reduction of parvalbumin in middle cerebral artery occlusion animal model.

Authors:  Dong-Ju Park; Ju-Bin Kang; Fawad-Ali Shah; Phil-Ok Koh
Journal:  Lab Anim Res       Date:  2021-02-25

10.  Reward-representing D1-type neurons in the medial shell of the accumbens nucleus regulate palatable food intake.

Authors:  Máté Durst; Katalin Könczöl; Tamás Balázsa; Mark D Eyre; Zsuzsanna E Tóth
Journal:  Int J Obes (Lond)       Date:  2018-06-15       Impact factor: 5.095

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.